NEO Earnings & Financial Statements
NeoGenomics, Inc.
$16.35
+$0.32(+2.03%)
59
Overall
60
Value
63
Tech
55
Quality
Market Cap
$2.06B
Volume
393.24K
52W Range
$7.07 - $20.05
Target Price
$19.72
NEO earnings and financial statements: NeoGenomics, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
NEO Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $727.33M | $660.57M | $591.64M | $509.73M | $484.33M |
| Cost of revenue | $413.04M | $370.47M | $347.04M | $321.83M | $297.27M |
| Operating income | -$115.88M | -$92.11M | -$107.74M | -$157.62M | -$118.75M |
| EBITDA | -$36.69M | $1.40M | -$14.73M | -$79.49M | $46.50M |
| Net income | -$108.03M | -$78.73M | -$87.97M | -$144.25M | -$8.35M |
| EPS (diluted) | $-0.84 | $-0.62 | $-0.70 | $-1.16 | $-0.07 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $1.36B | $1.64B | $1.68B | $1.74B | $1.87B |
| Total liabilities | $523.27M | $735.70M | $739.69M | $742.01M | $761.50M |
| Shareholders’ equity | $836.56M | $902.34M | $941.54M | $998.02M | $1.11B |
| Cash and equivalents | $159.62M | $367.01M | $342.49M | $263.18M | $316.83M |
| Long-term debt | $404.68M | $401.18M | $606.07M | $604.27M | $604.77M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | $5.23M | $7.02M | -$1.95M | -$65.99M | -$26.72M |
| Capital expenditure | -$27.01M | -$41.06M | -$28.75M | -$30.89M | -$64.14M |
| Free cash flow | -$21.78M | -$34.04M | -$30.70M | -$96.88M | -$90.86M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | NEO | $16.35 | +2.0% | 393.24K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |